Hospital Acquired Infections: Testing Markets

August 2012 | 117 pages | ID: H17ECD91DECEN
Kalorama Information

Abstracts

A nosocomial, or hospital-acquired, infection is a new infection that develops in a patient during hospitalization. It is usually defined as an infection that is identified at least forty-eight to seventy-two hours following admission, so infections incubating, but not clinically apparent, at admission are excluded. This type of infection is also known as a hospital-acquired infection (or more generically healthcare-associated infections). The following are among the hospital infections considered in this report:

• Acinetobacter Baumannii
• Clostridium Difficile
• Hospital-Acquired Pneumonia
• Pseudomonas Aeruginosa
• Staphylococcus Aureus
• Tuberculosis
• Urinary Tract Infections
• Vancomycin-resistant Enterococcus
• Ventilator-Associated Pneumonia

This report focuses on testing for nosocomial infections. The major consideration is given to bacterial nosocomial infections because a) they are the most frequent type of infections spread in the hospital setting, and b) the practical aspects of diagnosis and therapy are more meaningful based both on medial considerations and on market considerations. This report Hospital Acquired Infection Testing Markets looks at the market for diagnostics that address the growing nosocomial infection threat. As part of its coverage, the report includes the following information:

• Market Size Estimate and Growth Forecast for the HAI Diagnostics Market
• Issues and Trends Affecting Market
• Common Hospital (nosocomial) Infections
• Nosocomial Infection Statistics
• International Hospital Length of Stay Statistics
• The Role of Molecular Tests vs. Traditional
• Corporate Profiles of Key Suppliers

Market analysis in this report considers primarily the epidemiological considerations and the sizes patient groups both in the United States and globally, where available. We have accumulated the most recent data available, understanding that virtually no organization does extensive studies on these applications on a regular basis. Many studies are highly localized and may only apply to a community, state or country (more often countries that are not a part of the major markets for nosocomial diagnostic and therapeutic products). In many instances, we have had to draw from broader epidemiologic data, that is, on data that reach outside of the hospital environment in order to try and construct a picture of the nosocomial testing and treatment needs.

The primary focus of this report is on the bacterial form of nosocomial infections, and those with significant impact on the hospital setting and markets. In looking at these infections, we consider the diagnostic and therapeutic technologies that are currently available and attempt to project trends for diagnosing these infections. To some extent, we are limited by the activity of the industries associated with the diagnosis and treatment of these infections. For the most part, these activities are limited and the advanced technologies seen in other areas of medical application are not necessarily present in terms of microbiology.

Companies Profiled in the report include the following:

• Abbott Laboratories
• Alere
• Becton, Dickinson
• bioMerieux
• Cephei
• Gen-Probe
• Meridian Bioscience, Inc.
• Qiagen GmbH
• Roche
• Siemens AG

Contents

CHAPTER ONE: EXECUTIVE SUMMARY

Overview
Infection Control Summary
Scope and Methodology
Total Size and Growth of the Market
Issues and Trends Affecting Market
Leading Competitors

CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS

Overview
  Introduction to Pathogens
  Classification of Antibacterial Organisms
  Common Hospital (nosocomial) Infections
Hospital Units and Infection Risks
  Burn Units
  Intensive Care Units
  Emergency Departments
  General Infection Statistics
  Nosocomial Infection Statistics
  Hospital Length of Stay
  Populations at Risk for Infection
Demographics of the World
  Life Expectancy
Economic Trends
  Comparison Between Healthcare Spending and Real Health Outcomes
Infections and Drug Resistance
  Causes of Drug Resistance
  Drug Resistance in Select Populations
  Measures for Reducing Resistance
  Screening Hospitalized patients
Prevention Measures
  Potential Use of Copper for Reducing Infection
  Wide Area Disinfection Methods
  Software for Infection Detection and Control
The American Recovery and Reinvestment Act of 2009
  U.S. Statewide Standardized Infection Ratio
  State Level Case Study of HAI Admissions and Readmissions
  John T. Mather Memorial Hospital/Cepheid-Case Study
Manufacturer and Marketer Trends
  Trends in Partnerships and Alliances
  Developers Trends

CHAPTER THREE: HOSPITAL INFECTION TESTING PRODUCTS

Overview
Methods of TransmissionTesting Methods
  Drug-Resistance/Susceptibility Testing
  Genotypic Methods
Specific Nosocomial Disease Testing
  Acinetobacter Baumannii
  Clostridium Difficile
  Hospital-Acquired Pneumonia
  Pseudomonas Aeruginosa
  Staphylococcus Aureus
  Tuberculosis
  Urinary Tract Infections
  Vancomycin-resistant Enterococcus
  Ventilator-Associated Pneumonia
New Developments

CHAPTER FOUR: MARKET OPPORTUNITIES FOR HOSPITAL INFECTION TESTING

Market Considerations
Market Overview
Total Market Size and Forecast
  Hospital Infection Testing Market by Geographical Region
Competitive Analysis

CHAPTER FIVE: COMPANY PROFILES

Introduction
Abbott Laboratories
Alere
Becton, Dickinson
bioMerieux
Cephei
Gen-Probe
Meridian Bioscience, Inc.
Qiagen GmbH
Roche
Siemens AG

APPENDIX: LIST OF MAJOR PROVIDERS

List Of Exhibits

LIST OF EXHIBITS

CHAPTER ONE: EXECUTIVE SUMMARY
Table 1-1: Frequency of the Most Common Nosocomial Infections
Table 1-2: The World Market for Hospital Infection Testing/Diagnostics 2007-2016
Figure 1-1: The World Market for Hospital Infection Testing/Diagnostics 2007-2016
CHAPTER TWO: INTRODUCTION AND INDUSTRY TRENDS
Table 2-1: Burn Statistics
Figure 2-1: U.S. Hospital Admissions and Percent of Hospital-acquired Infections (HAIs)
Table 2-2: U.S. Hospital Length of Stay, Average by Age Group
Table 2-3: Average International Length of Stay, by Country 2010
Table 2-4: World Population at Risk for Serious Bacterial Infections,Secondary to Chronic Diseases by Selected Geographical Region, 2010
Figure 2-2: World Population at Risk for Serious Bacterial Infections, Secondary to Chronic Diseases by Selected Geographical Region, 2010
Table 2-5: Estimated World Population by Age and Geographical Region, 2010
Figure 2-3: Estimated World Population by Age and Geographical Region, 2010
Table 2-6: Average Life Expectancy in Years by Country 1980, 2004 and 2011
Figure 2-4: Average Life Expectancy in Years by Country 1980 and 2011
Table 2-7: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000 and 2010
Figure 2-5: Total Healthcare Expenditures as a Percent of GDP by Country 1990, 2000, and 2010
Table 2-8: Healthcare Spending, Obesity and Life Expectancy, 2011
Table 2-9: U.S. States Hospital Acquired Infection Standardized Infection Ratio (SIR)
Table 2-10: Pennsylvania State Analysis of HAI Readmissions and Related Costs, 2009
Table 2-11: Pennsylvania State Analysis of HAIs, 2009
CHAPTER THREE: HOSPITAL INFECTION TESTING PRODUCTS
Table 3-1: Recent Approvals for Hospital Infection Testing
Table 3-2: New Developments, Hospital Infection Testing, as of July 2012
CHAPTER FOUR: MARKET OPPORTUNITIES FOR HOSPITAL INFECTION TESTING
Table 4-1: The World Market for Hospital Infection Testing/Diagnostics 2007-2016
Figure 4-1: The World Market for Hospital Infection Testing/Diagnostics 2007-2016
Figure 4-2: The World Market for Hospital InfectionTesting/Diagnostics Estimated Market Share by Test Indication, 2011
Table 4-2: The World Market for Hospital Infection Testing/Diagnostics Estimated Products Sales by Geographic Region 2007-2016
Figure 4-3: The World Market for Hospital Infection Testing/Diagnostics Estimated Product Sales by Geographic Region 2007-2016
Figure 4-4: The World Market for Hospital Infection Testing/Diagnostics Estimated Market Share by Region, 2011
Table 4-3: The World Market for Hospital Infection Testing/Diagnostics Leading Suppliers’ Shares Estimates for 2011
Figure 4-5: The World Market for Hospital Infection Testing/Diagnostics Leading Suppliers’ Shares Estimates for 2011